- Merenstein, Daniel;
- Pot, Bruno;
- Leyer, Gregory;
- Ouwehand, Arthur C;
- Preidis, Geoffrey A;
- Elkins, Christopher A;
- Hill, Colin;
- Lewis, Zachery T;
- Shane, Andi L;
- Zmora, Niv;
- Petrova, Mariya I;
- Collado, Maria Carmen;
- Morelli, Lorenzo;
- Montoya, Gina A;
- Szajewska, Hania;
- Tancredi, Daniel J;
- Sanders, Mary Ellen
Probiotics are used for both generally healthy consumers and in clinical settings. However, theoretical and proven adverse events from probiotic consumption exist. New probiotic strains and products, as well as expanding use of probiotics into vulnerable populations, warrants concise, and actionable recommendations on how to work toward their safe and effective use. The International Scientific Association for Probiotics and Prebiotics convened a meeting to discuss and produce evidence-based recommendations on potential acute and long-term risks, risks to vulnerable populations, the importance for probiotic product quality to match the needs of vulnerable populations, and the need for adverse event reporting related to probiotic use. The importance of whole genome sequencing, which enables determination of virulence, toxin, and antibiotic resistance genes, as well as clear assignment of species and strain identity, is emphasized. We present recommendations to guide the scientific and medical community on judging probiotic safety.